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ABSTRACT
The fermentation of dietary fibre (DF) leads to the production of bioactive metabolites, the most 
volatile ones being excreted in the breath. The aim of this study was to analyze the profile of exhaled 
breath volatile metabolites (BVM) and gastrointestinal symptoms in healthy volunteers after a single 
ingestion of maltodextrin (placebo) versus chitin-glucan (CG), an insoluble DF previously shown to be 
fermented into short-chain fatty acids (SCFA) by the human microbiota in vitro. Maltodextrin (4.5 g 
at day 0) or CG (4.5 g at day 2) were added to a standardized breakfast in fasting healthy volunteers 
(n = 15). BVM were measured using selected ion flow tube mass spectrometry (SIFT-MS) throughout 
the day. A single ingestion of 4.5 g CG did not induce significant gastrointestinal discomfort. 
Untargeted metabolomics analysis of breath highlighted that 13 MS-fragments (among 408 obtained 
from ionizations of breath) discriminated CG versus maltodextrin acute intake in the posprandial state. 
The targeted analysis revealed that CG increased exhaled butyrate and 5 other BVM – including the 
microbial metabolites 2,3-butanedione and 3-hydroxybutanone – with a peak observed 6 h after CG 
intake. Correlation analyses with fecal microbiota (Illumina 16S rRNA sequencing) spotlighted 
Mitsuokella as a potential genus responsible for the presence of butyric acid, triethylamine and 
3-hydroxybutanone in the breath. In conclusion, measuring BMV in the breath reveals the microbial 
signature of the fermentation of DF after a single ingestion. This protocol allows to analyze the time- 
course of released bioactive metabolites that could be proposed as new biomarkers of DF fermenta-
tion, potentially linked to their biological properties.
Trial registration: Clinical Trials NCT03494491. Registered 11 April 2018 – Retrospectively regis-
tered, https://clinicaltrials.gov/ct2/show/NCT03494491
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Introduction
Dietary fibre (DF) are non-digestible polysacchar-
ides considered as beneficial for human health, 
namely through their effect on gut function such 
as the modulation of stool production.1 They are 
classified according to their chemical structure, 
their food source, their water solubility and viscos-
ity, or their fermentability.1 The categorization of 
DF as viscous soluble (e.g. pectin), nonviscous solu-
ble (e.g. inulin) or as insoluble (e.g. cellulose) is an 
attempt to link their physico-chemical properties to 
physiological effects. However, this may link to 
erroneous conclusions regarding their fermentabil-
ity by the gut microbiota. Indeed, several insoluble 
DF can be fermented by gut microbes, and could 
thus be considered as potential prebiotics.1,2 A pre 
biotic refers to a substrate that is selectively utilized 
by host microorganisms conferring a health bene 
fit.3 Chitin-glucan (CG) is an insoluble DF consid-
ered as a safe food ingredient by the European Food 
Safety Authority.4 It is extracted from the cell walls 
of the mycelium of Aspergillu niger fungi and is 
CONTACT Nathalie Delzenne nathalie.delzenne@uclouvain.be Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Brussels, 
UCLouvain, Université Catholique de Louvain, Brussels, Belgium.
*These authors contributed equally to this work.
Supplemental data for this article can be accessed on the publisher’s website.
GUT MICROBES                                              
2021, VOL. 13, NO. 1, e1862028 (16 pages) 
https://doi.org/10.1080/19490976.2020.1862028
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
composed of branched β-1,3/1,6 glucan linked to 
chitin via a β-1,4 linkage. Marzorati et al. demon-
strated that CG was fermented with enhanced 
short-chain fatty acids (SCFA) production (mainly 
propionate and butyrate) using an in vitro 
approach (Simulator of the Human Intestinal 
Microbial Ecosystem).5 In previous studies in 
rodents, we and others showed that CG signifi-
cantly improved metabolic parameters, an effect 
linked to an increase of butyrate-producing 
Roseburia spp. and reduced cardiovascular risk 
factors.6,7 In humans, CG administration for 
6 weeks reduced oxidized low-density lipoproteins 
(LDL) in the serum, the mechanism behind this 
observation being unexplored.8
The identification of bioactive metabolites pro-
duced upon fermentation of DF in the gut is impor-
tant to afford the biological events involved in 
health improvement, and to propose biomarkers 
of nutrient intake. Volatile organic compounds 
(VOCs) in the exhaled breath have been proposed 
as potential surrogate markers of gut dysbiosis in 
gastrointestinal diseases and diabetes mellitus.9,10 
Bacteria being a major source of volatile metabo-
lites, it was suggested that breath volatile metabo-
lites (BVM) such as H2, SCFA or alkanes may be 
indicators of host health.11,12
Usually, the analysis of exhaled breath biomar-
kers is carried out by means of gaz chromatogra-
phy-mass spectrometry (GC-MS), preferably in 
combination with a suitable enrichment technique 
prior to analysis. Although very powerful, GC-MS is 
not particularly compatible with routine clinical 
practice. It is a relatively slow technique, requiring 
analysis times that take on average 30–45 min for 
comprehensive analysis without post-run data 
processing.13 Alternatively, direct MS techniques 
such as selected ion flow tube (SIFT)-MS, proton 
transfer reaction (PTR)-MS and more recently sec-
ondary electrospray ionization (SESI) MS have 
gained more attention because they hold the pro-
mise of speed, selectivity, and sensitivity in a single 
instrument.14 SIFT-MS is particularly well suited 
for the purpose of exhaled breath analysis.15 It 
combines very soft chemical ionization under con-
trolled conditions with three precursor ions (H3O+, 
NO+, and O2+), preserving molecular ion integrity 
for maximum sensitivity and selectivity. Precursor 
ions are generated in situ from humidified air that is 
gently fed into a high energy microwave discharge 
source to create an ion plasma. Selected precursor 
ions are extracted from this plasma by means of 
a short upstream quadrupole and introduced in the 
flow tube, where they are thermalized by means of 
a high flow of helium and allowed to react with the 
sample molecules for a defined amount of time. 
During the reaction, formed product ions are 
diverted toward a downstream quadrupole by 
means of the excess helium flow where they are 
separated from each other and detected. Since reac-
tion conditions are accurately controlled, SIFT-MS 
allows direct quantification of target components in 
real-time from raw ion count rates and associated 
reaction kinetics. Typical concentration levels are 
situated at low parts per billion by volume levels. Of 
note, the applied precursor ions are very effective in 
ionizing a broad range of organic and inorganic 
components but they do not react with nitrogen, 
oxygen and carbon dioxide. Usually, SIFT-MS is 
applied in target mode, which means that only 
a limited set of components are measured 
simultaneously.15 If target components are not 
known, SIFT-MS is used in untargeted scan mode, 
where it provides pattern-based classification capa-
city, the identification of probable biomarkers, and 
retrospective quantification of target components.16
In the context of the project FiberTAG (Joint 
Programming Initiative “A Healthy Diet for 
a Healthy Life” 2017–2020 https://www.fibertag.eu/), 
we aimed to identify bioactive bacterial metabolites 
linking DF intake and gut microbiota-related health 
effect.17 In this present study, exhaled BVM have 
been analyzed by SIFT-MS,10,18) in healthy volunteers 
to monitor the potential interaction of a single expo-
sure to CG as insoluble DF with the gut microbiota.
Results
Characterization of the subjects (baseline fecal gut 
microbiota, SCFA composition and hydrogen 
production)
The interventions were conducted in March 2018 fol-
lowing the study design shown in Figure 1. Fifteen 
subjects respecting inclusion and exclusion criteria 
(Sup Data 1) were selected as H2-producers based on 
the lactulose test (Sup Data 2) and completed the 
study. Baseline characteristics of participants are 
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shown in Sup Data 3. Before the intervention, the 
mean energy intake was 2046 ± 130 kcal/day and 
their nutrient intakes were 229 ± 23, 81 ± 6, 70 ± 5, 
and 20 ± 4 g per day for carbohydrates, lipids, proteins, 
and fibre, respectively.
The overall composition of gut microbiota was 
assessed by the measure of both α-diversity and β- 
diversity indexes. Subjects seemed to display 
a different gut microbiota composition as shown 
by the principal coordinate analysis of the Bray- 
curtis index; subject I being the most distant from 
others (Figure 2a). However, this difference was 
reduced when the distance measure considers the 
fraction of branch length in a phylogenic tree, as 
assessed by the unweighted uniFrac distance; sub-
ject G being the most distant from others on this 
principal coordinate analysis (PCoA). α-Diversity 
related to bacterial richness (Observed OTU), even-
ness (Pielou), or both (Shannon) was systematically 
lower for subject I (Figure 2b). Gut microbiota 
analysis presented at the phylum level confirmed 
the lower α-diversity found for this subject for 
which Verrucomicrobia and Tenericutes were 
absent from its bacterial profile in feces (Figure 
2c). Those phyla were also absent in the fecal matter 
of subject N who presented again a low α-diversity 
indexes. Firmicutes was the most abundant bacter-
ial phylum for all subjects (> 60%) followed by 
either Bacteroidetes or Actinobacteria depending 
on the subject. The total amount of SCFA in the 
fecal matter is presented in Figure 2d. Subjects 
E and G exhibited the highest levels of fecal SCFA 
whereas subject L presented the lowest total 
amount of fecal SCFA. We noted lower proportions 
of valeric and iso-valeric acids in subject I as com-
pared to other subjects. Those SCFAs were not 
detectable for subject C (Figure 2d). The total 
amount of SCFA in all subjects varied between 
1 mg/g to 4 mg/g of fecal dry matter, acetate 
being the most abundant one.
Gastrointestinal tolerance after CG versus 
maltodextrin ingestion in healthy subjects
In order to evaluate the tolerance of ingesting CG 
after a unique intake during the breakfast, visual 
analogue scale (VAS) scores were recorded. The 
baseline scores of gastrointestinal parameters 
between the 2 test days were not significantly dif-
ferent (Sup Data 4). The evolution of the different 
scores throughout the day was not significantly 
affected by CG intake, suggesting a good gastroin-
testinal tolerance (Figure 3). Only flatulence was 
more important as soon as 6 h after CG intake, as 
compared to maltodextrin intake (p = .054).
BVM profile after single ingestion of CG or 
maltodextrin in healthy subjects
The SIFT-MS analysis was carried out using three 
precursor ions (H3O+, NO+, and O2+) to record 
the resulting fingerprints of the breath (untargeted 
T30minT0 T2h T4h T6h T8h T10h T12h
collation
Test day Maltodextrin (day 0): standard breakfast with maltodextrin (4.5 g)
Test day Chi!n glucan (day 2): standard breakfast with chi!n-glucan (4.5 g) 
7:00 am 8:00 pm
SIFT-MSGC-TCD




Figure 1. Overview of the study design.
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analysis) (Figure 4a). Principal component analysis 
(PCA) analysis of MS-fragments in overnight- 
fasted state (time 0 h), in preprandial state meaning 
before lunch (time 4 h) and in the postprandial- 
post absorptive state (time 6 h) showed that the 15 
subjects formed separate clusters depending on the 
time of measurement, and therefore on the nutri-
tional status (fasted, preprandial, postprandial). 
The clustering at time 6 h was more pronounced 
in CG than in the maltodextrin group, indicating 
a difference in BVM profile between both treat-
ments (Figure 4b). Before the lunch (time 4 h), 
the trends were distinct from the overnight fasting 
state (time 0 h) and we observed a slight overlap 
between both groups (Figure 4b). Interestingly, 
after the lunch at time 6 h, a clear separation 
(from partial least squares discriminant analysis 
(PLS-DA) analysis) appeared for participants that 





























































































































Figure 2. Gut microbiota and short-chain fatty acids (SCFA) composition in fecal matter of 15 healthy subjects before intervention days. 
(a) Principal coordinate analysis (PCoA) score plot of β-diversity estimated using the using the Bray-curtis and unweighted uniFrac 
indexes. (b) α-diversity indexes related to bacterial richness (Observed OTU), evenness (Pielou) or both (Shannon) for each subject. (c) 
Bar plots of relative abundance of phylum levels accounting for more than 0.5% for each subject. (d) Bar plots of SCFA concentration 
for each subject.
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Figure 3. Gastrointestinal tolerance assessed by visual analog scale of 15 healthy subjects about 8 symptoms after chitin-glucan intake 
of maltodextrin intake. Data are means ± SEM (p > .05; matched-pairs Wilcoxon signed-rank test on net AUC).
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received CG compared to subjects receiving mal-
todextrin and was linked to 13 MS-fragments 
(Figure 4c). The targeted analysis was conducted 
to identify 26 BVM known to be involved in energy 
metabolism in particular those coming from bac-
terial metabolism.11,12 Consistently with the untar-
geted analysis, we observed that only one BVM 
exhaled in the breath (pentane) was more impor-
tant on the test day with maltodextrin (Sup Data 5). 
All other BMV had similar value in fasted state 
upon both days (day 0 and day 2). The concentra-
tions (in ppm) of all BVM exhaled in the breath 
over time for both test days are presented in 
Supplemental Data 6. Repeated measures ANOVA 
revealed a significant effect for time and for subject 
inter-variation for all targeted BVM (p < .05). 
A significant effect of the treatment was obtained 
only with butyric acid, triethylamine, 2,3-butane-
dione, 3-hydroxybutanone, ethane, methanol, and 
pentane (repeated measures ANOVA p < .05). 
Figure 5 presents the evolution of exhaled SCFA 
over time corrected by the baseline value at a fasted 
state. Among all SCFA identified, the evolution of 
propionic acid and butyric acid in the breath was 
significantly affected after a single ingestion of CG. 
Of note, the level of exhaled propionic acid was 
PLSDA of MS-fragments for both groups
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Monte-Carlo test: p = 0.575
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Figure 4. Untargeted analysis of breath from 15 healthy subjects after chitin-glucan and maltodextrin intake. Principal component 
analysis (PCA) score plot of the MS-fragments from the SIFT-MS spectra (from H3O+, NO+ and O2+ ionizations) obtained in fasted state 
(time 0 h) the first test day (a) or in fasted state (time 0 h), in pre-prandial state (time 4 h) and in postprandial state (time 6 h) (b). PLS- 
DA (with cutoff 0.9) of 408 MS-fragments after chitin-glucan intake and maltodextrin intake at time 6 h (c). Statistical analysis was 
assessed by a Monte Carlo rank test.
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lower after CG intake than maltodextrin intake 
whatever the time considered. More importantly, 
exhaled butyric acid increased after CG intake after 
the lunch and reached the highest level at time 6 h 
in the postprandial state compared to participants 
ingesting maltodextrin. The evolution of other 
exhaled SCFAs was not significantly different 
between the 2 test days. Figure 6 revealed six 





























































































































Figure 5. Targeted short-chain fatty acids (SCFA) concentrations (changes from baseline) exhaled in breath of healthy subjects in 
response to chitin-glucan and maltodextrin intake. Data are means ± SEM (*p < .05; matched-pairs Wilcoxon signed-rank test on net 
area under the curve).
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other BVM with an AUC that was significantly 
affected after CG versus maltodextrin intake. 
Among them, triethylamine, 2,3-butanedione, 
3-hydroxybutanone (p = .054) and pentane fol-
lowed the same trends than the butyric acid with 
a peak observed at time 6 h for triethylamine, 
3-hydroxybutanone and 2,3-butanedione, and at 
time 8 h for pentane. Methanol increased whereas 
ethane decreased just after CG-breakfast intake and 
a peak was observed at 8 h for methanol. Although 
some of them were increased after CG ingestion, 
the evolution of well-known markers of gut fer-
mentation such as exhaled H2 or CH4 as well as 
other targeted BVM were not significantly affected 
after CG compared to maltodextrin intake (Sup 
Data 7). We observed that the highest levels of 
acetone, acetonitrile, acetic acid, propionic acid, 
caproic acid, 1- and 2-propanol, benzene, and ben-
zaldehyde were found at time 0 (meaning in the 
fasting state) since all changes from baseline were 
negative after treatment and throughout the 
test day for those metabolites (Figure 5, Sup 
Data 7). In accordance with the untargeted analysis, 
several identified BVM such as acetic acid, (iso) 
valeric acids, acetone, acetonitrile, ethanol, butanol, 
phenol, isoprene, methane, and H2S were different 
between the pre- and postprandial states (time 4 h 
versus time 6 h) without any significant effect of CG 
treatment. Isoprene was the sole BVM which 
decreased after lunch in both groups (Figure 5, 
Sup Data 7). We performed correlation analyses 
between different indexes of α-diversity and 
exhaled BVM (net AUC) in both groups 
(Spearman r and p values are given in Sup 
Data 6). Correlations obtained with observed 
OTU and Shannon indexes were not significant 
whatever targeted BVM exhaled in the breath 
when CG is consumed. In contrast, the Shannon 
diversity index was negatively and significantly cor-
related with butyric acid, methanol, triethylamine, 
and 3-hydroxybutanone exhaled in the breath 
throughout the day when no DF was consumed 
(placebo group). Relevant correlations were also 
seen with the Pielou index with C5 acids (valeric, 
isovaleric and 2-methylbutyric acids) that were 
exhaled in the breath (mostly after the lunch) but 
exclusively when CG is consumed. It is worth to 
note that the level of exhaled butyrate (at time 6 h 
and the net AUC) after CG intake was not 
correlated with the initial concentration of fecal 
butyrate (r = 0.40 and r = −0.07, respectively; 
p > .05). More importantly, baseline Mitsuokella 
relative abundance was the sole genus positively 
correlated with net AUC of exhaled butyrate (Sup 
Data 6). In addition, net AUC of triethylamine was 
positively correlated with Mitsuokella and 
Catenibacterium, 3-hydroxybutanone was posi-
tively correlated to Mitsuokella, Alloprevotella, 
Lachnospiraceae FCS020 group and 
Ruminococcaceae NK4A214 group whereas exhaled 
pentane was positively correlated to 
Faecalibacterium and 2,3-butanedione was posi-
tively correlated with Muribaculaceae metagenome, 
Clostridium sensu stricto, and Flavonifractor.
Discussion
Effects of DF are usually investigated using urine, 
blood, and fecal analysis, but exhaled breath is of 
increasing interest because it allows noninvasive 
sampling. There are almost 900 VOCs in the 
exhaled breath of healthy humans19 which could 
be considered as potential biomarkers of metabolic 
disorders, specific diets, or both. Consistently, 
breath analysis (mainly hydrogen and methane) is 
already used in clinics for monitoring gastrointest-
inal disorders.12,20–22 Recently, Rondanelli et al. 
reviewed biomarkers present in exhaled breath of 
gastrointestinal diseases and nutritional status.23 
For example, exhaled acetone has been reported 
to be an important biomarker of diabetes.9 A few 
studies have also monitored the effects of diet (glu-
ten-free diet, high versus low-fat dairy drink, high 
versus low fibre diets) on the composition of 
exhaled breath.12,24–27 In the present study, we 
compared for the first time the effect of unique 
ingestion of an insoluble DF (CG prone to be fer-
mented by the gut microbiota) versus maltodextrin 
(a fully digestible carbohydrate) as placebo on BVM 
profile in young healthy adults. The interpretation 
of our data considered characterization prior to 
intervention in terms of fecal microbiota composi-
tion and fecal SCFA. We hypothesized that some 
BVM may be the reflect of DF gut fermentation 
with respect to inter-subject variation.
It has already been described that the presence of 
some metabolites such as acetone, ethanol, iso-
prene, and methanol in the breath is conditioned 
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by the fasting state.11 In our study, the highest levels 
of acetone but also acetonitrile, acetic acid, propio-
nic acid, caproic acid, 1- and 2-propanol, benzene, 
and benzaldehyde were found at fasting state in the 
morning. The potential origin of such BVM was 
already discussed elsewhere focusing on diet, 
environmental exposure (exposure to air pollu-
tants), and biological pathways.11,28 Some of them 
were decreased after the breakfast without any 
further variation due to the lunch, the collation, 
or the CG intake whatever the time considered (1- 
and 2-propanol, benzene, and benzaldehyde). We 


































































































































Figure 6. Targeted breath volatile metabolites (BVM) concentrations (changes from baseline) exhaled in breath of healthy subjects 
significantly changed after chitin-glucan intake compared to maltodextrin intake. Data are means ± SEM (*p < .05; matched-pairs 
Wilcoxon signed-rank test on net area under the curve).
GUT MICROBES e1862028-9
hypothesized that the presence in a breath at time 
0 h of this kind of BVM with high affinity with fat 
tissue may be the result of the high rate of lipolysis 
at a fasted state. Other BVMs were different 
between the pre- and postprandial states without 
any significant influence of CG intake. It is the case 
of acetic acid, (iso)valeric acids, acetone, acetoni-
trile, ethanol, and methane for which levels 
increased after the lunch in both groups. Acetone, 
produced via fatty acid oxidation, has been one of 
the earliest identified gaseous disease biomarkers, 
being distinctively present in the breath of patients 
with diabetic ketoacidosis, hypoinsulinemic states, 
and starvation.29 Subtle acetone fluctuations also 
systematically occur in response to modest, physio-
logical changes in insulin/glucose levels.29 In con-
trast, ethanol is not produced by human cells, but 
small concentrations in blood and breath derive 
from the alcoholic fermentation of glucose by gut 
bacteria expressing pyruvate decarboxylase. 
Following carbohydrate ingestion, blood and 
breath ethanol increase.29 Furthermore, the levels 
of exhaled breath ethanol increased after intrave-
nously administered glucose load, supporting the 
hypothesis that glucose enrichment of gastrointest-
inal capillaries per se may stimulate gut bacterial 
fermentation to some degree.30 The source and 
physiological effect of isoprene in humans are mat-
ters of debate. In animals and humans, this inter-
mediary metabolite of cholesterol synthesis is 
formed in the liver from isopentenyl pyropho-
sphate (IPP) and its isomer (DMAPP).31 However, 
as this reaction is slow and may be insignificant at 
physiological pH values, it is unlikely to completely 
explain the endogenous isoprene production by 
animals. So far, two major metabolic pathways 
leading to DMAPP have been identified: the meva-
lonic acid (MVA) pathway and the 1-deoxy- 
D-xylulose-4-phosphate/2-C-methylerythriol 
5-phosphate (DOXP/MEP) pathway. The DOXP/ 
MEP pathway was demonstrated to prevail in 
plants and most bacteria, whereas the MVA path-
way is mainly present in higher eukaryotes. In 
bacteria, DMAPP is converted into isoprene enzy-
matically by isoprene synthase. Surprisingly, iso-
prene increased with the time of fasting and fell 
down in a postprandial state independently of the 
DF intake. Another study showed that isoprene 
concentrations did not change significantly 
following feeding with a liquid protein-energy 
meal.32 It would be interesti 
ng to assess the role of isoprene as a marker of 
cholesterol synthesis, which can be affected differ-
ently following meal composition. A pilot study of 
seven healthy subjects suggested that increased 
metabolic activity in the gastrointestinal tract after 
ingestion of a meal could explain, at least partly, the 
increase of BVM such as ethanol, 1-propanol, 
3-hydroxybutanone, propionic acid, and butyric 
acid.12 Here, we did not observe any change with 
a meal of propionic acid and 1-propanol. Anyway, 
our data led us to conclude that a lot of BVM from 
our targeted analysis, principally produced by host 
metabolism, reflected metabolic state rather than 
a response to a DF ingestion. In addition, our 
study revealed that bacterial metabolites coming 
from the gut microbiota and exhaled in the breath 
such as H2S, methane and SCFA (acetic acid, buty-
ric acid, (iso)valeric acids, propionic acid, caproic 
acid) may be influenced by the ingestion of a meal 
or by the fasting state.
Hexose and pentose sugars are fermented by 
isolated human colonic bacteria via pathways lead-
ing to the formation of SCFA, ethanol, and hydro-
gen depending on the strain and species.33 In 
particular, butyrate formation occurs in 
Firmicutes bacteria, either via butyrate kinase (in 
many Clostridium and Coprococcus species) or via 
butyryl CoA:acetate CoA transferase.34 Marzorati 
et al have shown that fermentation of CG led to an 
increased production of both propionate and buty-
rate in vitro.5 In the present study, a single intake of 
4.5 g CG led to an increase of exhaled butyrate 
suggesting that this SCFA is not restricted to enter-
ocyte metabolism, but may be absorbed in the cir-
culation and then released in the breath as 
a signature of gut fermentation of CG, since the 
increase did not appear when volunteers received 
placebo. We were unable to relate exhaled butyrate 
to fecal butyrate. It should be kept in mind that 
SCFA production mainly occurs in the proximal 
part of the colon where the availability of substrates 
is most abundant. Accordingly, up to 95% SCFA 
are rapidly absorbed by the colonocytes resulting in 
decreasing concentrations from the proximal to 
distal colon and only about 5% is excreted in 
feces.35 In addition, intestinal microbial fermenta-
tion is a dynamic process influenced by a wide 
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range of factors. Therefore, the levels of each meta-
bolite are a result of metabolic fluxes of highly 
variable rates, which are not adequately represented 
in steady-state metabolite profiles in feces. Our 
kinetic analysis offered the possibility to assess the 
dynamic processes of gut fermentation. 
Interestingly, exhaled butyrate after CG intake was 
positively correlated with Mitsuokella from the 
Firmicutes phylum. It has been demonstrated that 
concentration of exhaled methanol increased from 
a physiological level of ~0.4 ppm up to ~2 ppm 
a few hours after eating around 500 g of fruits, the 
effect being principally due to pectin 
fermentation.11,36 Here, the basal levels of breath 
methanol were in the same range than the physio-
logical level but did not reach a concentration 
higher than 0.5 ppm. In addition, bacterial fermen-
tation in the mouth or throat can partly explain 
increased postprandial levels of exhaled breath 
BVM.12 Breath methanol increased already just 
after taking the CG with the breakfast, suggesting 
that this metabolite was not a reflect of CG fermen-
tation in the lower part of the gut. The kinetics of 
triethylamine release was different, since it 
increased 4 h after CG intake with a peak obtained 
at time 6 h as observed for butyric acid but the 
range of changes was very weak (maximum 0.005 
ppm). Although no literature exists about meta-
bolic pathway explaining a potential origin from 
gut bacteria, the kinetic study performed in the 
present study supported the hypothesis that this 
BVM appeared following gut fermentation of CG 
as observed for butyric acid. We found that produc-
tion in the breath was positively correlated with the 
presence of Mitsuokella and Catenibacterium in the 
fecal matter. Breath ethane decreased after CG 
intake whereas pentane followed the same kinetics 
than exhaled butyric acid. The presence of pentane 
in exhaled breath is considered as a result of lipid 
peroxidation of polyunsaturated fatty acids in cel-
lular membranes, a process mediated by free radi-
cals and oxidative stress.10 One study reported that 
exhaled pentane was dependent on dietary linoleate 
intake, and was blunted upon an antibiotic treat-
ment, an observation that leads them to conclude 
that intestinal bacteria were a major source of 
breath pentane in addition to endogenous mem-
brane lipid peroxidation.11,37 Since CG can slightly 
modify lipid absorption in the upper part of the 
gut,6 it is conceivable that the higher pentane exha-
lation could be linked to the higher production of 
this metabolite from undigested fatty acids by spe-
cific gut microbes. Data show that lactobacilli can 
produce 3-hydroxybutanone (acetoin) and 
2,3-butanedione (diacetyl).38 The production of 
3-hydroxybutanone and 2,3-butanedione has 
already been studied on different Lactobacillus 
strains growing on Jerusalem artichoke juice rich 
in inulin that served as substrate.38 Their produc-
tion is related to citrate metabolism through the 
citrate–oxaloacetate–pyruvate–acetolactate–acet-
oin/diacetyl pathway, where pyruvate is considered 
as the precursor. In our study, although 3-hydro-
xybutanone and 2,3-butanedione were exhaled 
after CG ingestion, no correlation was found with 
lactobacilli. Regarding the correlations obtained 
with observed α-diversity indexes, we can conclude 
that the richness or both abundance and evenness 
of the species present in the gut microbiota were 
not crucial to determine the response to CG in 
terms of exhaled microbial metabolites mostly pro-
duced after the lunch (butyric acid, triethylamine, 
pentane, 2,3-butanedione, and 3-hydroxybuta-
none). However, the bacterial richness was deter-
minant for some of those bacterial metabolites 
(butyric acid, triethylamine, and 3-hydroxybuta-
none) exhaled throughout the day when no DF 
was consumed (placebo group). Interestingly, 
3-hydroxybutanone production in the breath was 
positively correlated with Mitsuokella, the same 
bacteria revealed for butyric acid production. The 
genus Mitsuokella, comprising only two named 
species, are Gram-negative obligate anaerobes that 
utilize fermentable carbohydrates to form acetate, 
lactate, and succinate.39 Of these two species, 
M. multacida is regularly found in the intestinal 
tract of humans and appears to be responsive to 
diet changes. The acids produced were potentially 
available to other acid-utilizing bacteria for the 
formation of butyrate, such as Roseburia.40
In conclusion, this study showed that CG intake 
changed the exhaled BVM profile and that meal 
intake influenced the BVM profile. Even if the 
limitation of the study is to focus on a small cohort 
and refer to hydrogen producers only, we have 
validated a protocol allowing to analyze the effect 
of DF intake in the morning on the profiling of 
breath metabolites throughout the day, showing 
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that postprandial – postabsorptive period is prob-
ably the most relevant timing for the evaluation of 
BVM. Exhaled butyric acid, triethylamine, pentane, 
3-hydroxybutanone, and 2,3-butanedione are 
reflecting the bacterial metabolism after CG intake. 
This implies that analysis of BVM in exhaled air can 
be used as a dynamic approach to noninvasively 




The FiberTAG study is an interventional mono-
centric study including two test days aiming at char-
acterizing the fermentation of CG (Kiotransine® 
from KitoZyme, Belgium) versus maltodextrin 
(Cargill, Belgium), a nonfermentable digestible car-
bohydrate given as placebo, by assessing the volatile 
compounds released in the breath. For this purpose, 
blinded subjects received a single administration of 
maltodextrin (4.5 g) and two days later, a single 
administration of CG (4.5 g). After the single admin-
istration of CG fibre or maltodextrin given together 
with the breakfast, the kinetic of BVM production 
was measured repeatably during 12 h. Healthy sub-
jects were recruited by the Center of Investigation in 
Clinical Nutrition (CICN-UCLouvain) by displaying 
posters on the university site and by mails, by social 
networks, local newspapers and local flyers disposed 
in shops and doctor’s offices in nearby cities. Subjects 
were pre-screened by phone or mail using a question 
naire to test if they met the inclusion criteria listed in 
Supplemental Data 1. The participants were invited 
to perform a screening test using lactulose to select 
H2-producers. Forty subjects passed the screening 
lactulose test at least 4 weeks before the intervention. 
Briefly, fasted subjects (at least 10 h) received an oral 
load of 10 g of lactulose; then, exhaled H2 was mea-
sured every 30 min for 4 h using Lactotest 202 
(Medical Electronic Construction, MEC). 
A minimal increase of 10 ppm of H2 during three 
successive measurements was considered as the cri-
teria of subject selection. No increase should be 
observed in the first 30 min to avoid subjects with 
small intestinal bacteria overgrowth. After the 
screening test, 15 subjects were selected respecting 
inclusion and exclusion criteria (Sup Data 1) and 
were subjected to a medical examination with the 
physician investigator to verify that they were 
healthy. At least 12 days before the first test day, 
the volunteers were asked by a dietician to follow 
dietary recommendations to avoid eating fibre-rich 
food products containing high amounts of prebiotic 
DF more than once a week. These foods comprised, 
among others whole grains, artichokes, Jerusalem 
artichokes, salsifies, leeks, onions. Prebiotics and 
probiotics supplementation as well as the consump-
tion of fibre-enriched-food were forbidden. The sub-
jects were asked to complete a food diary for 3 days 
the week before the intervention. The Nubel Pro 
program and the table of composition from Nubel 
2010 were used to assess macronutrient and total 
fibre intake. Up to 4 days before the intervention 
period, stool samples were collected and stored 
directly at −20°C for further transport within 
4 days to the CICN for storage at −80°C until ana-
lyses. This study was approved by the local ethical 
committee (Comité d’Ethique Hospitalo-Facultaire 
UCLouvain/Cliniques Universitaires Saint-Luc) and 
written informed consent was obtained from all sub-
jects. The trial was carried out in accordance with the 
Good Clinical Practice as required by the following 
regulations: the Belgian law of 7 May 2004 regarding 
experiments on human persons and the EU 
Directive 2001/20/EC on Clinical Trials (registration 
at clinicaltrials.gov as NCT03494491).
Intervention days
Both test days were organized in the same way. An 
overview of the study design is shown in Figure 1. 
Subjects were blinded regarding the compound they 
received. The evening before the two intervention 
days, subjects were asked to eat rice and meat, with-
out vegetables and to avoid alcohol. Fasted subjects 
(from 9 pm the day before) arrived at 7 am at the 
CICN. The study coordinator reviewed the inclusion 
and exclusion criteria and verified if instructions 
were adequately followed. After mouth wash (with 
Perio Aid Intensive Care), breath samples were taken 
to analyze BVM at baseline. In the meantime, sub-
jects were asked to complete a VAS questionnaire 
about the eight gastrointestinal symptoms usually 
described after the consumption of fibre. Then the 
subject received a standardized breakfast composed 
of white bread and butter, with 240 ml of water and 
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4.5 g of CG or the placebo. The breakfast should be 
eaten within 15 min. Breath samples were collected 
after 30 min and then every 2 h during 12 h after the 
CG or placebo ingestion to measure BVM. In the 
meantime, every hour, subjects were asked to com-
plete the VAS questionnaire. Of note, 2 h after the 
CG or placebo ingestion, subjects were free to drink 
water. Five hours after the start, the subjects received 
a standardized lunch composed of white bread, ham, 
and cheese. At 4 pm (8 h after the start) subjects 
received a collation (sweet waffle). The test day 
ended at 8 pm.
Gastrointestinal symptoms
The 100-mm VAS about the eight gastrointestinal 
(cramps, bloating, rumbling, discomfort, flatulence, 
burps, gastrointestinal reflux, and nausea) was filled 
out at baseline and every hour for 12 h after the 
ingestion of CG or maltodextrin load. The scales 
were scored by measuring the distance (in mm) 
from 0 with a ruler. Scores were expressed as 
changes from baseline in cm.
Breath volatile metabolites (BVM) analysis
Breath samples were collected into bags (FMONP. 
SBAG1.01 from MEC R&D SPRL, Belgium) before 
and 30 min after the ingestion of CG or the placebo 
and then every 2 h for 12 h. The bags were directly 
sent to Interscience (Louvain-La-Neuve, Belgium) 
for BVM measurement (within 2 h after the harvest 
of the exhaled air) by GC using a TCD detector (for 
H2 analysis every 4 h; Trace 1310 GC, Thermo 
Scientific, USA) and using SIFT-MS (for other 
BVM; Voice 200ultra, Syft Technologies, New 
Zealand). For this last methodology, the reagent 
ions (H3O+, NO+, and O2+) were generated by 
a microwave air discharge at 0.5 Torr, selected by 
using a quadrupole mass filter and injected into 
a stream of helium carrier gas in the flow tube. All 
the ion products of the chemical ionization reaction 
and un-reacted reagent ions were monitored by 
a quadrupole mass spectrometer in the full scan 
mode in the mass-to-charge ratio (m/z) range of 
10–200 amu (unit mass resolution) over 60 s. Bags 
filled with helium were used as blank. The full scan 
data (ion counts per second) averaged over the 
sampling time for each m/z value was used for the 
statistical analyses. LabSyft software package (ver-
sion 1.4.4, Syft Technologies) was used for the mass 
spectrum acquisition and data exportation as 
comma-separated values (CSV) files. In total, three 
data sets were obtained from H3O+, NO+, and O2 
+ ionizations. We targeted volatile metabolites 
known to study energy metabolism and to study 
the gut-related metabolic effects of DF, in particular 
those known to be a reflect of gut fermentation 
(coming from bacterial metabolism).11,12 Identified 
BVM were expressed as changes from baseline in 
ppm. Concentrations in ppm (presented in Sup 
Data 5–6) were determined by using pseudo-first- 
order reaction kinetics according to the equation 
[A] = [P+] ICFP/k [R+] ICFR (LabSyft software, 
Syft Technologies, New Zealand); [A] is the concen-
tration of the identified compound in ppm; [P+] 
and [R+] are the signal in counts per second of 
product ion and precursor ion, respectively; tr is 
the reaction time (s); k is the rate constant of the 
reaction between R+ and A (cm3 s−1 molecule−1); 
ICFP and ICFR, used to normalize raw ion counts 
for ion transmission inefficiencies, are mass- 
dependent transmission functions that are deter-
mined by analysis of a calibration gas mixture with 
known composition and concentrations.41
Gut microbiota analysis
Bacterial DNA was extracted from fecal samples 
from baseline (before interventions) using the 
QIAamp DNA Stool Mini Kit (QIAGEN, Hilden, 
Germany), as previously described.42 All samples of 
this study were sequenced in the same run. α- 
diversity indexes and β diversity indexes were cal-
culated using QIIME2. PCoA plot of the β-diversity 
indexes was visualized using R software. The raw 
sequencing data are deposited into the Sequence 
Read Archive (SRA) of NCBI (http://www.ncbi. 
nlm.nih.gov/sra) under BioProject PRJNA636138.
Fecal SCFA analysis
SCFAs were analyzed in the native fecal samples as 
previously described.42
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Data integration and statistical analysis
Data are expressed as means ± SEM. Baseline values 
were compared by matched-pairs Wilcoxon signed- 
rank test; to adjust for multiple testing, the p-value of 
the Wilcoxon test was adjusted with a false discovery 
rate (FDR) of 5% according to the Benjamini-Hoch 
berg procedure (q-value, significant if q < 0.05). Net 
area under the curve (AUC) was calculated for each 
symptom recorded every hour and for each identified 
BVM recorded every 2 h after maltodextrin or CG 
intake. Wilcoxon matched-pairs signed rank test was 
used to compare net AUC. In addition, repeated mea-
sure ANOVA was performed to compare the evolu-
tion of BVM over time. For the gut microbiota 
analysis, relative abundances performed in QIIME2 
are expressed as means and SEM and were calculated 
on R for each taxon. PCA, PCoA and PLS-DA models 
were built based on selected variables in R (v3.5.1, 
package “ade4” and “mixOmics”). For PLS-DA, 
a loading > 0.9 was chosen. For PCA, statistical differ-
ences among the group were determined by Monte 
Carlo permutations to handle nonparametric data 
distributions (n = 999, implemented in R). 
Correlation analysis was performed between BVM 
and α-diversity or all genera identified (genera with 
a mean of relative abundance <0.01% were removed) 
by Spearman’s correlation test using the “corrplot” 
package in R. A significance level of p < .05 (q-value 
for adjusted p value, using FDR correction) was 
adopted for all analyses.
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